FIG 1.

EV-A71 infection increases the mortality of humanized mice, accompanied by a decrease in the neurobehavioral scores. (A) Humanized mice at different ages were inoculated i.p. with or without EV-A71 (10⁸ PFU/mouse). The survival rate of mock-infected mice (n = 10) and EV-A71-infected mice (n = 10 for 4-week-old and 5-week-old groups; n = 5 for the remaining groups) at the indicated weeks postinfection is shown. (B to E) Humanized mice and NSG mice at different ages were inoculated i.p. with EV-A71 (10⁸ PFU/mouse). The survival rate of humanized mice (n = 8 for 4-week-old group; n = 5 for the remaining groups) and NSG mice (n = 10 for 4-week-old group; n = 5 for the remaining groups) at the indicated weeks postinfection is shown. The survival rate of mice between two groups is compared by Kaplan-Meier analysis via a log-rank test. (F) Humanized mice at 4 weeks of age were inoculated i.p. with or without EV-A71 (10⁸ PFU/mouse). The neurobehavioral scores of mock-infected mice (n = 10), EV-A71-infected surviving mice (n = 6), and moribund mice (n = 4) at the indicated weeks postinfection are shown. Data are expressed as means ± SEM. *, P < 0.05; **, P < 0.01 (relative to the mock-infected group).